Ultrasound-Guided Microwave Ablation Vs. Surgery for Low-Risk PapilaryThyroid Carcinoma

NCT06725576 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 201

Last updated 2024-12-31

No results posted yet for this study

Summary

This study aims to investigate the efficacy and prognosis of ultrasound-guided and gene-based microwave ablation (MWA) versus surgical treatment in patients with low-risk papillary thyroid carcinoma (PTC). By analyzing genetic testing results, the study explores the impact of genetic mutations on treatment selection for low-risk patients, providing more precise molecular biological evidence for treatment choices and prognosis evaluation of thyroid cancer. This prospective study collects clinical data from patients diagnosed with PTC at Sun Yat-sen Memorial Hospital of Sun Yat-sen University between January 2022 and November 2024, who underwent genetic testing prior to treatment, and assesses efficacy and complications through long-term follow-up.

Conditions

  • Thyroid Cancer, Papillary

Interventions

PROCEDURE

Ablation

Thyroid ablation performed under ultrasound guidance to treat low-risk papillary thyroid carcinoma.

Sponsors & Collaborators

  • National Natural Science Foundation of China

    collaborator OTHER_GOV
  • Guangzhou Science and Technology Innovation Commission,China

    collaborator UNKNOWN
  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    lead OTHER

Principal Investigators

  • Miaoyun Long, MD · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2025-03-04
Completion
2025-03-04

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06725576 on ClinicalTrials.gov